About: Targeting Herpetic Keratitis by Gene Therapy

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Targeting Herpetic Keratitis by Gene Therapy Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Targeting Herpetic Keratitis by Gene Therapy
Creator	Ferrari, Stefano Desseaux, Carole Gailledrat, Marine Ponzin, Diego Elbadawy, Hossein
Source	PMC
abstract	Ocular gene therapy is rapidly becoming a reality. By November 2012, approximately 28 clinical trials were approved to assess novel gene therapy agents. Viral infections such as herpetic keratitis caused by herpes simplex virus 1 (HSV-1) can cause serious complications that may lead to blindness. Recurrence of the disease is likely and cornea transplantation, therefore, might not be the ideal therapeutic solution. This paper will focus on the current situation of ocular gene therapy research against herpetic keratitis, including the use of viral and nonviral vectors, routes of delivery of therapeutic genes, new techniques, and key research strategies. Whereas the correction of inherited diseases was the initial goal of the field of gene therapy, here we discuss transgene expression, gene replacement, silencing, or clipping. Gene therapy of herpetic keratitis previously reported in the literature is screened emphasizing candidate gene therapy targets. Commonly adopted strategies are discussed to assess the relative advantages of the protective therapy using antiviral drugs and the common gene therapy against long-term HSV-1 ocular infections signs, inflammation and neovascularization. Successful gene therapy can provide innovative physiological and pharmaceutical solutions against herpetic keratitis.
has issue date	2012-12-26(xsd:dateTime)
bibo:doi	10.1155/2012/594869
bibo:pmid	23326647
has license	cc-by
sha1sum (hex)	54125da57282e24d5bcc4c1b60fa54ba1ad784be
schema:url	https://doi.org/10.1155/2012/594869
resource representing a document's title	Targeting Herpetic Keratitis by Gene Therapy
has PubMed Central identifier	PMC3541562
has PubMed identifier	23326647
schema:publication	J Ophthalmol
resource representing a document's body	covid:54125da57282e24d5bcc4c1b60fa54ba1ad784be#body_text
is schema:about of	named entity 'viral envelope' named entity 'HSV-1' named entity 'vector' named entity 'vector' named entity 'lentivirus' named entity 'cornea' named entity 'gene transfer' named entity 'Viral replication' named entity 'HSV-2' named entity 'HSV-1' named entity 'corneal neovascularisation' named entity 'transcriptional' named entity 'corticosteroid' named entity 'plasmid DNA' named entity 'gene therapy' named entity 'genome' named entity 'VEGFA' named entity 'antisense' named entity 'gene expression' named entity 'drug delivery systems' named entity 'adaptive immunity' named entity 'prophylaxis' named entity 'cornea' named entity 'HSV-1' named entity 'Synthetic Peptide' named entity 'gene gun' named entity 'Antibody' named entity 'VEGFR1' named entity 'Homing Endonucleases' named entity 'HSV-1' named entity 'Electroporation' named entity 'gene therapy' named entity 'HIV' named entity 'base stacking' named entity 'Electroporation' named entity 'gene therapy' named entity 'gene transfer' named entity 'HSV' named entity 'Lentivirus' named entity 'transferrin' named entity 'capsid protein' named entity 'toxicity' named entity 'herpetic keratitis' named entity 'developed world' named entity 'coreceptor' named entity 'Retrovirus' named entity 'double-stranded DNA' named entity 'gene therapy' named entity 'gene expression' named entity 'ribozymes' named entity 'infection' named entity 'signalling molecules' named entity 'target specific' named entity 'adolescence' named entity 'Deoxyribonucleic acid' named entity 'antisense oligonucleotides' named entity 'meganucleases' named entity 'alkaline' named entity 'HSV-1' named entity 'viral genome' named entity 'gene therapy' named entity 'gene therapy' named entity 'genome' named entity 'transgenes' named entity 'antiviral drug' named entity 'serotypes' named entity 'adeno' named entity 'transgene' named entity 'lentivirus' named entity 'age-related macular degeneration' named entity 'adeno-associated virus' named entity 'PCR' named entity 'latency stage' named entity 'corneal tissue' named entity 'clinical trial' named entity 'introns' named entity 'genome sequences'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software